Silver Book Fact

In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.

Hill J, Futterman R, Mastey V, Fillit H. The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan. Managed Care Interface. 2002; 15(3): 63-70. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11925682&dopt=AbstractPlus

Reference

Title
The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan
Publication
Managed Care Interface
Publication Date
2002
Authors
Hill J, Futterman R, Mastey V, Fillit H
Volume & Issue
Volume 15, Issue 3
Pages
63-70
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Current research supported by the National Institute of Neurological Disease Orders and Stroke (NINDS) at NIH is using animal models to study progression of the disease and develop new drugs…  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease in 2050 by…  
  • The U.S. Food and Drug Administration has approved 5 drugs that have proven to temporarily slow the worsening of Alzheimer’s disease symptoms for an average of 6 – 12 months…  
  • A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.  
  • Some studies have indicate that the management of high cholesterol, type 2 diabetes, high blood pressure, overweight or obesity, and other cardiovascular risk factors may help avoid or delay cognitive…